mfn-cus-2019

Nanologica announces that the United States Patent and Trademark Office has issued Nanologica’s patent titled ”Improved method for stem cell differentiation in vivo by delivery of morphogenes with mesoporous silica and corresponding pharmaceutical active ingredients”. The patent protects Nanologica’s technology platform for the delivery of growth factors for stem cell based therapy and provides evidence of successful translation from in vitro to in vivo for regeneration, long term survival and differentiation of motor neurons when

Nanologica and AstraZeneca have entered into an agreement for the evaluation of Nanologica’s pending patented technology, applied to AstraZeneca materials. The purpose of the project is to evaluate if Nanologica’s platform can improve the formulation of an API. The collaboration includes both in vitro and pre-clinical in vivo studies. The partnership project is an evaluation project lasting for one year, worth MSEK 1,5. ” This cooperation is a fine example of the potential our technology